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The CD2 receptor functions as an adhesion and signal molecule in T cell recognition. Multimeric 
binding of CD2 on T  cells to its physiologic ligand LFA-3 on cognate partner cells in vitro 
efficiently augments the antigen-specific T cell signal delivered by the T cell receptor/CD3 complex. 
The precise contribution of the antigen-nonspecific CD2-LFA-3  interactions to T cell immune 
responses in vivo, however, has been difficult to assess. Here we analyzed  the role of CD2 in 
the murine immune response using a nondepleting anti-CD2 monoclonal antibody that induces 
a marked, reversible  modulation of CD2 expression on murine T and B cells in situ. This modulation 
is dose and time dependent, specific for CD2, and does not require the Fc portion of the antibody. 
Anti-CD2  antibodies  [rat  IgG1  or  F(ab')2] significantly inhibit  the CD4 +  T  cell-mediated 
response to hen egg lysozyme and the cytotoxic CD8 + T  cell response to a syngeneic tumor 
cell line. In both cases, anti-CD2 antibodies are only effective when administered before or within 
24 h after antigen priming. The suppression of the antitumor response corresponds to a sixfold 
reduction of specific  cytotoxic T lymphocyte  precursor cells and results in the abrogation of protective 
antitumor immunity. Anti-CD2 antibodies also affect the humoral immune response to oxazolone: 
the isotype switch from specific IgM to IgG1 antibodies is delayed, whereas the IgM response 
is unaltered. In addition, a single antibody injection results in sustained polyclonal unresponsiveness 
of T  cells irrespective  of antigen priming and CD2 modulation. These results document that 
CD2-mediated signals induce a state of T  cell unresponsiveness in vivo. 
T 
he differentiation, activation, and effector phase of T cells 
is determined and regulated by interactions of an array 
of receptors on T cells with their specific ligands on cognate 
partner cells. Interactions of the T  cell receptor with the 
MHC/antigen complex determine the specificity of T  cell 
recognition. Interactions between the surface receptor pairs 
CD8 and MHC class I, CD4 and MHC class II, lymphokine 
function-associated antigen 1 (LFA-1)  t and ICAM-1/2, or 
CD2 and LFA-3 provide cosignals which augment the specific 
signal and regulate the adhesion process (1-8). This multiplicity 
of receptor pairs allows for a subtle regulation of T cell rec- 
ognition and underlines the importance of this process for 
the immune system. Among the "auxiliary" recognition mol- 
ecules CD2 has been most intensely studied. CD2 is a 50-55 
kD membrane glycoprotein which is expressed on 95%  of 
1 Abbreviations used in this paper: CTbp, cytotoxic T lymphocyte precursor; 
HEL, hen egg lysozyme; ICAM, intercellular adhesion molecule; LFA, 
lymphocyte  function-associated  antigen; PEC, peritoneal exudate cells; PPD, 
protein purified derivative; SEB, staphylococcal enterotoxin B. 
thymocytes early on during intrathymic T  cell maturation 
and on most peripheral T  cells and natural killer cells, al- 
though species differ with respect to CD2 expression on T 
cell subsets (9-11). So far mice provide an exception in that 
murine CD2 is also expressed on B cells (12-14). The physi- 
ological ligand  for  human  CD2  has  been  unequivocally 
identified as LFA-3, a widely distributed cell surface glyco- 
protein (15). Numerous studies revealed a dual function for 
CD2 as a signal and adhesion molecule. The signal function 
is most dearly documented by the activation of mature T 
cells by a combination of certain anti-CD2 antibodies (Abs) 
(16, 17) and the ligand of CD2 on SRBCs (18) and addition- 
ally the potentiation of T cell activation by crosslinking CD2 
and the TCR with bispecific Abs in vitro (19). The adhesion 
function has been originally demonstrated by blocking T cell- 
target cell binding with anti-CD2 and anti-LFA-3 antibodies. 
Although the affinity between soluble CD2 and LFA-3 mol- 
ecules is low, the adhesion provided during cell-cell contact 
is the sum of multimeric interactions between both mole- 
cules on apposing membranes (20). The signal function has 
been assigned to the membrane proximal part of the cyto- 
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CD2.  The adhesion function resides in the outer extracel- 
lular domain encoded by exon 2 (3, 6, 21). Both functions 
can be dissected experimentally, whereby a signal-defective, 
adhesive CD2  molecule is far less effective in augmenting 
T  cell activation than the intact, signal competent molecule 
(22). Whether CD2 can serve as an antigen-independent T 
cell activation receptor ("alternative pathway") or merely as 
a  coreceptor for the TCK in vivo remains  unclear  (23). 
The apparent redundancy in T  cell interaction molecules 
raises the question whether CD2-LFA-3 interactions are in- 
dispensable for T cell recognition in vivo, or can be compen- 
sated for by other receptor pairs. Earlier studies have shown 
that anti-CD2 Abs can block T  cell activation in vitro sug- 
gesting an important  role for CD2 in this event (24).  The 
contribution  of CD2  to the immune response in vivo has 
been difficult to assess given the lack of appropriate studies 
in animal models.  Here we report on experiments using  a 
mAb against murine CD2, which efficiently modulates CD2 
expression on lymphocytes in vivo. This modulation of CD2 
expression has profound effects on T  cell-mediated immune 
responses in vivo. 
Materials and Methods 
Mice.  DBA/2 and C3H/He mice, 8-10 wk of age, were ob- 
tained from the Zentrale Versuchstierzuchtanstalt,  Hannover, FRG; 
Balb/c mice were bred at the Institute of Genetics, Cologne. Animals 
were kept under specific  pathogen-free conditions in isolators during 
the whole course of experimentation. 
Reagents.  The rat IgG1 anti-murine CD2 mAb 12.15A (25) 
and the control Abs anti-CD5 (rat IgG2a, 53-7.3,  reference 31) 
and anti-tenascin (rat IgG1, 576, reference 26, kindly provided by 
Dr. Faissner, Institute of Neurobiology, University of Heidelberg) 
were semipurified  from ascites fluid by Protein G affinity chroma- 
tography. Purified mAbs were administered i.p.  in 200/zl sterile 
PBS. F(ab')2 fragments of mAb 12.15A were prepared according 
to Rousseaux et al. (27). Briefly, Abs (10 mg/ml) were extensively 
dialyzed first  against  pH 2.8  (0.1 M  sodium formate) and then 
against  pH 4.5, (0.1 M sodium acetate),  subsequently 1% pepsin 
(wt/wt) (Boehringer-Mannheim) was added for 4 h at 37~  and 
the reaction was stopped by neutralizing the pH with 1 M Tris 
buffer.  F(ab')2 fragments were purified from undigested Abs and 
smaller fragments by Mono Q ion-exchange FPLC chromatography. 
The following mAbs were used for staining either as purified 
reagents or directly coupled to FITC, PE, or biotinylated: anti- 
CD3 (500 A3, reference 28), anti-or ~  TCR (H57.597, reference 
29), anti-CD4 (GK 1.5, reference 30), anti-CD8 (53-6.7, reference 
31) anti-Thy 1.2 (30H12, reference 31), anti-LFA-1 (FD 18.5, refer- 
ence 32),  and anti-B220 (RA3-3A1,  reference 33). 
Hen egg lysozyme (HEL) and staphylococcal enterotoxin B (SEB) 
were purchased from Sigma Chemical Co. (Munich, FRG), pro- 
tein purified derivative  (PPD) from Behringwerke AG (Marburg, 
FRG), Con A and myoglobin (Myo) from Serva (Heidelberg, FRG). 
Recombinant IL-2 was a gift of Cetus Immune (Emeryville, CA) 
and rlL-4 a gift from Dr. W. M~iller, Cologne. 
The DBA/2 mouse derived tumor cell line ESb is a spontaneous, 
highly metastatic variant of the methylcholanthrene-induced T cell 
lymphoma L5178Ye (Eb) (34). Tumor cell lines were passaged in 
RPMI 1640 (Gibco, Paisley, UK) containing 5  x  10-5 M 2-ME, 
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10 mM Hepes, pH 7.3, 2 mM glutamine, and 10% FCS. The cells 
were routinely tested to be free of mycoplasma and virus infections. 
Quantitative Flow Cytometry.  Staining of thymocytes, mesen- 
teric lymph node cells, splenocytes, and peritoneal exudate cells was 
performed as described previously (35). Goat anti-rat IgG-PE, rabbit 
anti-hamster Ig-FITC, or streptavidin-PE  (Jackson Lab., Avondale, 
PA) were used as second stage reagents. Analysis was performed 
on a FACScan  |  cytometer (Becton & Dickinson, Heidelberg, FRG) 
recording 10,000 events for single color and 20,000 events for dual 
color analysis. Dead cells and nonlymphoid cells were excluded from 
analysis by a combination of forward and side scatter gating. Data 
were processed  with FACScan  |  Research software. 
Immunization with HEL.  C3H/He mice were immunized sub- 
cutaneously at the base of the tail with 100/zg HEL emulsified 
in  100 #1 PBS/CFA (1/1;  vol/vol). 7 d  after immunization,  the 
draining lymph nodes were removed and cells were cultured in 96- 
well microtiter plates  (2  x  105 cells/well)  with various concen- 
trations of HEL and control antigens. Cultures were set up in tripli- 
cates from pooled lymph node cells of two to three mice, incubated 
for 4 d under standard conditions, and pulsed for the last 12 h be- 
fore harvesting with  1 #Ci  [3H]TdR/well (2 Ci/mmol,  Amer- 
sham, Braunschweig, FRG). Incorporation of [3H]TdR was mea- 
sured according to standard procedures. 
Immunization with Syngeneic Tumor Cells.  DBA/2 mice were 
injected with 5  x  104 live ESb tumor cells in 50 #I PBS into the 
external ear under anaesthesia.  Injection at this site proved to be 
most effective in inducing antitumor immunity and thus preventing 
local tumor growth and metastasis (36). 7 d after priming the mice 
received a second injection with 107 inactivated ESb cells i.p. 3 d 
after the second immunization peritoneal exudate cells (PEC) and 
splenocytes were removed. PECs were tested directly in a 4 h SlCr 
release  assay for antitumor cytotoxicity ("secondary response"), 
whereas splenocytes were restimulated with syngeneic tumor cells 
for 4 d in vitro and then assayed for ESb-specific cytotoxicity ("ter- 
tiary response") as described previously (37). The parental tumor 
cell line Eb,  which does not express  the ESb-specific tumor an- 
tigen, was always included as a negative target cell control. Al- 
though Eb cells are sensitive to NK cells, lysis of Eb cells did not 
exceed 10%. We showed previously that ESb-specific cytotoxicity 
is exerted by CD8 + T cells which recognize a class I MHC (K  a) 
associated  ESb-specific antigen (34). 
Limiting dilution analysis of PECs and splenocytes was performed 
according to a protocol described previously (37). 
T Cell Activation Assays.  Flat-bottomed 96-well microtiter plates 
were coated with various concentrations of purified anti-CD3 or 
anti-criB TCK mAbs by preincubating the plates with the titered 
Abs in 100/zl of serum free medium for 20 h at 37~  followed 
by  extensive  washing.  Unseparated  lymph  node  cells  (2  x 
10S/well) or thymocytes (5  x  10S/well) were added in complete 
medium and cultured for 2-3 d. Alternatively, T cells were stimu- 
lated with Con A  (2,5/~g/ml)  or graded doses of SEB in flat- 
bottomed %-well plates. Allogeneic MLR responses were measured 
after cocultivation of 2  x  105 DBA/2 lymph node cells with 2 
x  105  irradiated  C57B1/6  splenocytes/well  for  3  d  in  flat- 
bottomed 96-well plates.  T cell proliferation was measured as de- 
scribed  above. 
Immunization with Oxazolone.  BALB/c mice received 100 #g 
of phOXCSA (2-phenyl oxazolone coupled to chicken serum al- 
bumin, referred to as oxazolone) i.p. which was precipitated by 
alum (38).  I d before and 7, 14, and 28 d after priming the mice 
were tail-bled and their serum IgM and IgG1 titers of anti-oxazolone 
Abs were determined in an ELISA assay using isotype-specific mAbs. 
Mice pretreated with 0.5-1 mg anti-CD2 Ab 1 d before antigen 
priming were compared to PBS-injected controls. 
Anti-CD2 Antibodies Prevent T Cell-mediated Immunity In Vivo Results 
Modulation of CD2 Expression In Viva  The previously de- 
scribed mAb 12.15A (25) against mouse CD2 was used to 
study the role of CD2 during the immune response in vivo. 
A  single injection of purified anti-CD2 mAb i.p.  led to a 
significant  modulation of CD2 expression on both T  and 
B calls in peripheral and central lymphoid organs, the mean 
fluorescence being reduced by 80% (T cells) and 73% (B cells) 
(Fig. 1). Modulation was defined by highly reduced binding 
of anti-rat IgG-PE and biotinylated anti-CD2 Abs to lym- 
phoid  cells. The  mAb-mediated  modulation  was  dose- 
dependent, 100 #g intact IgG per animal being sufficient to 
induce maximal modulation. The same degree of CD2 modu- 
lation was achieved with a single injection of purified F(ab')2 
fragments, albeit at an ~  10-fold higher dose (Fig. 2). CD2 
modulation did not result in comodulation of CD3, B220 
(Figs. 1 and 2 B), TCR oz//~, CD4, CD8, LFA-1, and Thy-1 
surface molecules (data  not shown). 
Maximal modulation was effected 20 h after Ab injection 
and persisted for ~3 d, thereafter CD2 expression was gradu- 
ally regained and control CD2 levels were attained by day 
14 (Fig. 3). The anti-CD2 mAb [intact IgG and F(ab')~.] led 
to a transient increase in the frequency of T cells by 5-20% 
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Figure 1.  Modulation of CD2 on peripheral  T and B cells  in vivo. DRA/2 
mice were injected with Img anti-CD2 Ab i.p. and 20 h later mesenteric 
lymph node cells were double-labehd  with CD2-biotin/streptavidin-PE 
and CD3-FITC or B220-FITC antibodies. Note the reduced expression 
of CD2 (reduction of mean fluorescence value by 75%) and the unaltered 
expression of CD3 and B220. CD2 positive cells are indicated in percent. 
959  Gficke]  et al. 
A 
100' 
80 
~,  60 
e,  40 
g 
O 
20 
1  0,5  0,1  0,05 
B 
100' 
80' 
60' 
~"  40' 
8 
0 
o~  20' I 
1 
dose  of mAb  injected  (mg) 
0,05 
￿9  PBS 
[]  anti-CD2 F(ab')2 
[]  anti-CD2 IgG1 
Figure 2.  Modulation of CD2 is dose-dependent. DBA/2 mice were 
injected with different doses of intact or F(ab')2 fragments of anti-CD2 
Abs. 48 h later lymph node cells  were labeled  with CD2-biotin/streptavidin- 
PE (A) or CD3-FITC (B). F(ab')2  fragments were ,x, 10 times less efficient 
than intact IgG Abs in inducing modulation in vivo. Cells with surface 
fluorescence above control staining with streptavidin-PE alone scored as 
positive. Each value represents one animal. In all experiments control mice 
received an equal volume of PBS. 
(as assessed by four independent markers,  data not shown) 
in spleen and lymph nodes and by day 8-14 to a relative de- 
crease in numbers of T cells by 10-30% accompanied by a 
proportional increase in B cells. By day 30-40 post-injection 
the frequency of CD4 + and CD8 + T cells ranged between 
85 and 100% of control levels. (Fig. 3). There was no consis- 
tent change in the absolute frequency of peripheral lympho- 
cytes following Ab treatment. 
Thus anti-CD2 Abs induced a marked modulation of CD2 
receptors on T and B cells, which was specific for CD2, re- 
versible, independent of the Fc-portion of the Ab, and site- 
independent. 100" 
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Figure 3.  Time course of CD2 modulation in vivo. DBA/2 mice re- 
ceived 0.5 mg anti-CD2 Ab and at the time intervals indicated mesenteric 
lymph node cells were labeled as described  in Fig.  2.  Note the time- 
dependent  reversion of CD2 modulation and  the  transient  increase of 
CD3 + cells. Each value represents  one animal. 
Anti-CD2  Abs  Inhibit  the Immune Response of CD4 +  T 
Cells to Hen Egg Lysozyme In Viva  The efficient modula- 
tion of CD2 expression on murine T  and B cells in vivo al- 
lowed us to assess the role of the CD2 receptor in the im- 
mune response in vivo. Does the highly reduced expression 
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Figure 4.  Anti-CD2 mAbs suppress  the CD4 + T  cell-mediated  re- 
sponse to HEL. C3H/He mice received 0.5 mg intact anti-CD2 or anti- 
CD5 Ab (A) or 1 mg F(ab')2 fragments  of the anti-CD2 Ab (B) 1 d be- 
fore immunization with HEL. 7 d later the proliferative response of cells 
from draining lymph nodes to the antigens indicated was measured. Both 
protocols resulted  in marked  suppression  of the HEL-specific response. 
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Figure 5.  Anti-CD2 Abs only affect the early phase of HEL priming. 
C3H/He mice received I mg of anti-CD2 Ab I d before or various days 
after priming with HEL and the specific proliferative response of draining 
lymph node cells was analyzed in vitro.  Anti-CD2 Abs were no longer 
effective, when administered  24 h after priming or later. 
of CD2 molecules perturb the interactions of effector precursor 
cells with accessory cells and thus influence the recruitment 
of antigen-specific lymphocytes in situ? The in vivo priming 
of  CD4 +  T  helper  cells  was  studied  by  immunizing 
C3H/He mice with HEL in CFA. Anti-CD2 Abs were ad- 
ministered 1 d before immunization. They reduced the antigen- 
specific proliferation of primed lymph node cells by more than 
50% as compared to control animals, likewise the prolifera- 
tive response of T cells against PPD, and an irrelevant antigen 
(myoglobin) was markedly inhibited. Anti-CD2 F(ab')2 frag- 
ments reduced the antigen-specific T cell response to a similar 
extent (Fig.  4).  This effect was specific for anti-CD2 Abs 
and not seen with an anti-CD5 (Fig.  4 A) or a rat control 
IgG1 Ab (data not shown). 
To delineate the critical phase during priming at which 
anti-CD2 Abs interfere, anti-CD2 Abs were administered be- 
fore and at different intervals after antigen injection. Anti- 
CD2 Abs were effective  when given simultaneously (data not 
shown) or 1 d before antigen priming. When administration 
of anti-CD2 Abs, however, was delayed by 1 or more d with 
respect to antigen injection, they proved ineffective (Fig. 5). 
These results demonstrate that modulation of CD2 expres- 
sion on murine lymphocytes interferes with the earliest phase 
of priming of CD4*  T  helper cells in vivo. 
Anti-CD2 Abs Inhibit  the CD8 + T  Cell-mediated In  Vivo 
Immune Response to Syngeneic Tumor Cells.  The immune re- 
sponse of DBA/2 mice against the syngeneic tumor ESb has 
been well characterized (34). These tumor cells express tumor- 
associated transplantation antigen(s) which can induce a long 
lasting antitumor response. Priming with these tumor cells 
recruits MHC-restricted,  tumor antigen-specific CD8 §  T 
effector cells which confer protective immunity against tumor 
cells upon adoptive transfer (39).  The in vivo induction of 
these CD8 + T effector cells is dependent on antigen-specific 
CD4 + T helper cells (36).  Mice received a primary and 7 d 
later a secondary immunization with syngeneic tumor cells, 
960  Anti-CD2 Antibodies  Prevent T  Cell-mediated  Immunity In Vivo 3 d thereafter spleen cells were removed and restimulated with  100' 
inactivated tumor cells in vitro to reveal tumor-specific cyto- 
toxic T cells. When mice were pretreated with anti-CD2 Abs  80 
one day before or simultaneously  with first tumor cell priming, 
the in vivo induction of cytotoxic antitumor T  cells was  o  .>_  60 
significantly reduced (Fig. 6). The reduction of the tumor- 
specific CTL  response could not be overcome by addition 
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(A) Anti-CD2 Abs suppress the CD8 + T cell mediated im-  Figure 6. 
mune response to a syngeneic tumor. DBA/2 mice were immunized  twice 
with ESb tumor cells (day 0 and 7), splenocytes were removed at day 10 
and restimulated in vitro with the same tumor cells for 4 d without or 
with addition of recombinant Ib2 or -4. Specific antitumor cytotoxicity 
was measured in a standard SlCr release assay, nonspecific cytotoxicity as 
tested against Eb tumor cells was <5%. Experimental mice received I mg 
anti-CD2 Ab 1 d before the first immunization.  Anti-CD2 Abs suppressed 
the specific  CTL response irrespective of addition of interleukins. For each 
group cells from three animals were pooled. (B) Anti-CD2 Abs reduce 
the frequency of antitumor specific  CTL-p sixfold. DBA/2 were immunized 
twice with the syngeneic tumor cell line ESb (day 0 and 7) and at day 
10 peritoneal exudate cells were removed and directly assayed for the fre- 
quency of tumor-specific CTL-p. Control group: f =  1/3,606 (shaded areas 
indicate the 95% confidence limits: 2,709-5,394),  anti-CD2 Ab treated 
group: f =  1/20,928 (15,883-30,66% For details see Materials  and Methods 
and reference 37. 
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Figure 7.  Anti-CD2 Abs abrogate protective antitumor immunity in 
vivo. DBA/2 mice received I mg anti-CD2 Ab 1 d before immunization 
with ESb tumor cells. Whereas control mice developed protective immu- 
nity and rejected the tumor cells, all treated mice died of tumor spread 
within 17 d.  Each group comprised  10 mice. 
of low doses of IL-2 or -4 to the culture in vitro,  although 
IL-4 markedly enhanced the control response (Fig. 6 A). 
Suppression of the antitumor CTL response by anti-CD2 
Abs corresponded to a reduction in the frequency of specific 
CTL-precursors (CTL-p) as determined by limiting dilution 
analysis. Splenic  CTL-p frequencies  were reduced from 1/18,901 
to 1/46,439 and peritoneal CTbp frequencies from 1/3,606 
to 1/20,928 in mice pretreated with 500 #g Ab/mouse. (Fig. 
6 B). This reduction in tumor cell-specific T cell immunity 
was sufficient to abrogate protection against lethal tumor cell 
spread. All mice treated  with anti-CD2 Abs  (10/10)  suc- 
cumbed to the tumor load within 17 days, whereas 90% of 
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Figure 8.  Anti-CD2 Abs affect the early phase of tumor cell priming 
in vivo. DBA/2 mice were immunized with ESb tumor cells as described 
in legend to Fig. 6. The specific antitumor cell cytotoxicity of peritoneal 
exudate cells  was assessed  directly ("secondary  response") (A) whereas spleno- 
cytes were restimulated in vitro ("tertiary response") (B). Mice received 
0.5 mg anti-CD2 Ab before or various intervals after the first priming. 
Specific cytotoxicity was only reduced, when mice were treated within 
24 h after priming. 
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Figure 9.  Anti-CD2 Abs induce sustained  T cell unresponsiveness  against 
HEL. DBA/2 mice received 1 mg of anti-CD2 Abs at different time in- 
tervals before immunization  with HEL. 7 d after antigen  priming draining 
lymph node cells were removed and their proliferative response was mea- 
sured. Even 20 d after Ab administration mice did not develop a T cell- 
specific response. 
the mice in the control group (9/10) were still  alive 40 d 
after tumor cell inoculation (Fig.  7). 
To define the window of susceptibility to anti-CD2 Ab 
treatment in this immune response, Abs were administered 
before (day -1) and after (day +1,  +3,  +6) the first priming 
with tumor cells. Peritoneal cells were tested for spedfic CTLs 
ex vivo without further restimulation  ("secondary response", 
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Figure 10.  Anti-CD2 Abs induce sustained T  cell unresponsiveness 
against syngeneic tumor cells. DBA/2 mice received 1 mg of anti-CD2 
Ab at different time intervals  before the first immunization  with ESb tumor 
cells. The "secondary" (A) and "tertiary" (B) cytotoxic antitumor  response 
was assessed according to the protocol in legend to Fig. 6. Even 20 d after 
Ab injection mice remained unresponsive towards the tumor cells. 
Fig. 8 A), whereas spleen cells were restimulated with inac- 
tivated  tumor cells in vitro ("tertiary response"  Fig. 8 B). 
A significant reduction in the cytotoxic response was observed 
in both protocols,  when Abs were administered within 24 h 
after initiation of the immune response.  3 d after priming 
anti-CD2 Abs did no longer interfere with the development 
of antigen-specific  T  cells  in vivo (Fig.  8). 
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Figure 11.  Anti-CD2 Abs induce a sustained reduction in polyclonal T cell responsiveness. DBA/2 mice were pretreated with 1 mg anti-CD2 Ab 
28 d before removal of mesenteric lymph node cells. T cells were polyclonally activated by graded doses of matrix-bound  anti-CD3 Abs (.4), the superan- 
tigen SEB (B), and allogeneic stimulator  cells (C).  Even 28 d after treatment with anti-CD2 Abs peripheral T  cells remained less responsive than 
those of control mice. 
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Figure 12.  Anti-CD2 Abs delay  the IgGl-specific  Ab response to ox- 
azolone: BALB/c  mice  received 1 mg anti-CD2 Ab I d before  immuniza- 
tion with oxazolone. 7 and 14 d after priming the specific  IgM and IgG1 
Ab titers against oxazolone  were  determined.  Treatment  led to highly re- 
duced IgG1 titers at day 7 (A) which regained control levels by day 14 
(B). In contrast, specific  IgM titers were unaffected  by anti-CD2 Abs at 
day 7 and 14. Serum antibody titers as measured  by ELISA are shown 
(dilution 1:10). Values represent the ~  _+ SD of four animals. 
Thus, anti-CD2 Abs suppress  the clonal development of 
specific CD8 + T effector cells against syngeneic tumor cells 
by interfering at an early stage of the immune response in vivo. 
Anti-CD2 Abs Induce Sustained T Cell Unresponsiveness  In 
Vivo Independent  of CD2 Modulation.  The stage at which anti- 
CD2 Abs suppressed the HEIcspecific and antitumor cell re- 
sponse coincided with maximal modulation of CD2 expres- 
sion (see Fig.  3) and thus  the effect may be explained by 
blocking CD2-LFA-3 interactions resulting in reduced adhe- 
sion between T cells and cognate partner cells. Given the dual 
function of CD2 as an adhesion and signal molecule, we tested 
whether the immuno-suppressive effects of anti-CD2 Abs 
do require CD2 modulation. Mice were pretreated with anti- 
CD2 Abs 5,  10, or 20 d before priming with HEL or ESb 
tumor cells, whereby CD2 modulation was reversed 10-14 
d post-injection (Fig.  3). Pretreatment with anti-CD2 Abs 
even 20 d before priming resulted in a nearly complete inhi- 
bition of the anti-HEL, -PPD (Fig.  9), and secondary and 
"tertiary" antitumor cell response (Fig. 10, A and B). When 
mice were killed 28 d after application of anti-CD2 Abs, CD2 
expression was  restored with  regard  to  the frequency of 
CD2 + cells/organ and the density of CD2 receptors/ceU and 
lymphocytes were phenotypically indistinguishable from those 
of control mice and no residual rat IgG was detectable in 
vivo (data not shown). In addition to antigen-spedfic T cell 
responses peripheral T cells of treated mice were less respon- 
sive to polyclonal activation by TCR crosslinking, activation 
by SEB, and allogeneic stimulator cells (Fig.  11, A-C). This 
latter result indicates that anti-CD2 Abs but not control Abs 
induced reduced polyclonal responsiveness of T cells in vivo 
which was independent of CD2  surface expression. 
Effects of  Anti-CD2 Abs on the Humoral  Immune  Respons~  In 
distinction to other species (rat, sheep, human) in mice CD2 
is expressed both on T  and B cells (12-14).  Anti-CD2 Abs 
modulate CD2 expression on B and T  cells to a similar ex- 
tent (Fig.  1) and may thus affect T-B cell recognition and/or 
B effector cells directly. Production of Ab subclasses of the 
IgG isotypes is strictly T  helper cell-dependent while IgM 
Ab production is less T cell-dependent. We analyzed the effect 
of anti-CD2 Abs on the well characterized humoral response 
of BALB/c mice to oxazolone (38). A single injection of an- 
tigen in adjuvant results in production of specific IgM Abs 
(day 7) followed by IgG1 Abs (day 7-14).  Pretreatment of 
mice with 0.5 or 1 mg anti-CD2 Abs did not influence the 
production of antigen-specific IgM Abs, whereas the IgG1 
response was significantly reduced at day 7 (Fig.  12, A  and 
B). The reduction of IgG1 titers, however, was transient and 
by day 14 the IgG1 titers of treated mice did not differ from 
those of controls (Fig.  12 B). These observations have been 
reproduced in three independent experiments. Thus, anti-CD2 
Abs obviously caused a delay in the isotype switch from IgM 
to IgG1 Abs. This result is consistent with an indirect role 
of CD2 in the humoral response probably affecting T helper 
cell function. 
Discussion 
The human CD2 receptor has been extensively character- 
ized with regard to its structure and function primarily based 
on in vitro studies (1-8). Thus detailed knowledge has accu- 
mulated on delineating the function of the extracellular and 
cytoplasmic domains of CD2 which are involved in trans- 
membrane signaling and adhesion to LFA-3. In contrast, little 
is known about the contribution of the CD2 receptor to ac- 
tivation, donal expansion, and distribution of antigen-specific 
lymphocytes during an immune response in situ.  Using a 
mAb against murine CD2 we report experiments which sup- 
port a significant role of CD2 in T  cell immunity in vivo. 
Coinjection of anti-CD2 Abs with a soluble or cellular an- 
tigen results in marked inhibition of CD4 + and CD8 + T 
cell-mediated, antigen-specific immune responses. Moreover, 
963  Giickel  et al. injection of anti-CD2 Abs induces a prolonged downregula- 
tion of T cell responsiveness independent of antigen exposure. 
The immunosuppressive effects are specific for anti-CD2 
Abs and cannot be explained by ablation of CD2 + lympho- 
cytes.  A  single injection in adult or multiple injections of 
anti-CD2 Abs into newborn mice did not lead to numerical 
depletion of thymocytes or peripheral lymphocytes, more than 
98% of which express CD2. The unaltered presence of CD2- 
synthesizing cells in Ab-treated animals was easily revealed 
when lymphocytes were cultured in vitro in the absence of 
Abs. Reexpression of modulated CD2 occurred within 24 h 
(9). Moreover, nondepleting F(ab')2 fragments of anti-CD2 
Abs induce CD2 modulation and immunosuppression in vivo. 
CD2 modulation was dose and time dependent, whereby 
a single dose of 0.1-5 mg purified Ab resulted in maximal 
modulation within 24 h gradually reverting to normal CD2 
expression levels within  10-14  d.  Biodistribution  of lzsI- 
labeled anti-CD2 Abs revealed a rapid clearance from blood 
and a quantitative accumulation in spleen, lymph nodes and 
bone marrow. Within 32 h splenic radioactivity fell to <5 % 
of initial levels indicating a rapid internalization,  degrada- 
tion and excretion of iodinated degradation products (40). 
This fate of labeled 12.15A Ab confirms the cytofluorometric 
analysis on the modulation kinetics of CD2 surface expression. 
Given the dual function of CD2 as an adhesion and signal 
molecule the immunosuppressive effects of anti-CD2  Abs 
could be due to interference with either of these functions. 
Injection of 0.5-1  mg of anti-CD2 Abs results in marked 
modulation of CD2 surface expression for ~ol wk (Fig. 3). 
This lowered expression of CD2 would diminish the contri- 
bution to cell-cell adhesion by CD2/LFA-3 interactions and 
the cooperation between CD2 and TCR/CD3 in T cell acti- 
vation and may thus impede the recruitment of antigen-specific 
T cell precursors. Alternatively, crosslinking of CD2 by biva- 
lent Abs [IgG or F(ab')2] ~ould deliver a signal which in- 
duces T cell unresponsiveness irrespective of CD2 surface ex- 
pression and antigen recognition. Either of these mechanisms, 
"adhesion/signal deficiency" or "unresponsiveness" of T cell 
precursors in vivo may thus explain the immunosuppression 
which is observed when antigen is injected at the time of 
CD2 modulation. Since a reduction in polyclonal T cell re- 
sponsiveness  (Fig.  11) was only observed 8-21 but not 2 d 
after Ab injection (data not shown), we favor "adhesion/signal 
deficiency" by CD2 modulation to account for the reduced 
response when antigen and anti-CD2 Abs are coinjected. It 
this context it is worth mentioning that the mouse homo- 
logue of human LFA-3 has not yet been identified and the 
natural ligand for murine CD2 remains to be defined. 
Anti-CD2 Abs are only effective when administered within 
24 h after antigen priming. This narrow window of suscep- 
tibility indicates a role for CD2 in the early recruitment phase 
of antigen-specific precursor cells. Once primed, differentia- 
tion and expansion of antigen-specific cells obviously pro- 
ceeds independent of CD2-mediated signals.  Similar results 
have been observed for the development of TNP-specific, 
CD8 +  T  cells  (41).  This  time-dependency of CD2  im- 
munomodulation was stricter for the CD4 + T  cell-medi- 
ated response to HEL than for the antitumor response (com- 
pare Figs. 5 and 8). Whether this is due to different kinetics 
of these particular immune responses or due to the effector 
subsets involved (CD4 + versus  CD4 + plus CD8 + T  cells) 
remains to be darifed. 
The immune response to HEL clearly identifies CD4 + T 
cells as target cells for CD2-mediated suppression. Likewise 
the specific albeit transient effect of anti-CD2 Abs on the 
IgGl-specific immune response against oxazolone is likely to 
be due to insufficient help by CD4 + T cells. The unaltered 
IgM response argues against a direct effect on B cells.  At 
present it is open whether CD2 modulation on B cells directly 
affects B cell-specific functions. In contrast to the T  cell re- 
sponse, the effect on the humoral immune response, how- 
ever, is short-lived. 
The antitumor response is mediated by CD8 + T effector 
cells.  Protective immunity against ESb tumor cells can be 
induced after injection of live tumor cells in the ear within 
2-3 d and it involves mutticeUular interactions including in- 
tradermal antigen presenting cells (Langerhans cells), CD4 + 
helper cells,  and CD8 + CT1,p.  These critical interactions 
take place within 24-48 h after priming (34, 36). Frequency 
analysis revealed a significant reduction of specific CT1,p in 
treated mice. The deficient cytotoxic response could not be 
overcome by supplying exogenous II,2 or -4 during restimu- 
lation  in  vitro  indicating  an  insufficient  recruitment  of 
interleukin-responsive CT1,p in vivo. This defect could be 
due to abrogation of help by CD4 + T  cells and/or direct 
impairment of CD8 + T cell function At present the effects 
on all three antigen-specific responses are compatible with 
lack of CD4 + T  helper cell function and it remains open 
whether CD8 + T  cells can be direct targets of CD2-me- 
diated immune suppression. Interestingly, the CD4 § T cell 
subset has been shown to be selectively susceptible to anergy 
induction by SEB (42). 
It is of interest to note that the anti-CD2 mAb 12.15A 
did not affect T ceU-mediated immune responses in vitro (e.g., 
syngeneic  and  allogeneic  MLI~,  Con  A,  TCR/CD3  or 
SEB-mediated T cell activation, secondary responses to HEL 
and tumor cells, data not shown) when added to cultures. 
Likewise, the anti-CD2 Ab on its own did not activate ma- 
ture T cells (as measured by cell proliferation, induction of 
IL-2 receptor expression or raise in intracellular Ca  2+) even 
when coupled to sepharose.  The reason for this difference 
may relate to the rapid modulation of CD2 receptors in vivo 
after Ab injection (Figs.  1 and 3), whereas the Ab does not 
modulate CD2 on resting T cells in vitro (43). Additionally, 
different levels of adhesion receptors on precursor T cells and 
memory cells (2, 8), the different microenvironments in situ 
and in tissue culture and the different modes and kinetics 
of T cell activation involved my contribute to this difference. 
Alternatively, the different in vitro and in vivo effects may 
be a characteristic of the mAb used in this study (44).  In 
particular, for rat and human CD2 it has been shown that 
Abs directed against different epitopes may exert different bi- 
ological effects in vitro (16,  17)  and possibly in vivo. 
Beyond inhibition of antigen-specific immune responses, 
964  Anti-CD2 Antibodies Prevent T  Cell-mediated Immunity In Vivo a single injection of anti-CD2 Abs induced a sustained reduc- 
tion in polyclonal T  cell responsiveness (Figs.  9-11), which 
did not correlate with CD2 modulation,  altered expression 
of TCR./CD3, CD4, CD8, and LFA-1 or reduction of T cells. 
While the in vivo response to HEL or tumor cells was nearly 
completely suppressed even 20 d after Ab injection,  T  cells 
were still responsive to activation by anti-TCR/CD3  Abs, 
SEB and allogeneic stimulator cells in vitro (Fig.  11) but less 
so than control cells.  Thus,  functional unresponsiveness in 
vivo corresponds to a mere quantitative reduction in T  cell 
responsiveness in vitro. A similar dose shift in polyclonal T 
cell activation has been observed in mice which are trans- 
genic for TCR V~sl and express the corresponding autoan- 
tigen Mlg. These mice did not display autoreactivity but de- 
veloped a state of functional  tolerance by anergy (45). 
The  CD2-mediated  state  of T  cell  unresponsiveness  is 
reminiscent of peripheral T cell unresponsiveness induced by 
inappropriate antigen presentation in vitro or in vivo (46-49), 
recognition of superantigens in vivo (42, 50), and adminis- 
tration of nondepleting  anti-CD4  or anti-CD8  Abs at the 
time of antigen priming (51). In contrast to these protocols 
of peripheral tolerance induction,  CD2-mediated unrespon- 
siveness is not confined to antigen-specific or subset-defined 
T cells. The mechanism and significance of this CD2-mediated 
"negative" signal remains a matter of speculation. In the con- 
text of the two signal hypothesis (46) crosslinking of CD2 
could provide signal one (either directly via an CD2-specific 
or indirectly via a CD3-dependent signal pathway [52]) which 
in the absence of signal two would render T cells unrespon- 
sive. In addition to induction of anergy among Vas + T cells, 
the superantigen SEB has recently been shown to induce partial 
deletion of this T cell subset in vivo (50). In two out of three 
experiments  we observed that  the frequency of peripheral 
CD4 + and CD8 + T  cells was reduced by 10-15%  2-4 wk 
after anti-CD2 Ab injection possibly indicating heterogeneity 
among T cells with regard to deletion by CD2-signaling or 
redistribution  of T  cells  in vivo. 
Preliminary data indicate that the CD2-mediated unrespon- 
siveness is readily induced in peripheral  lymph node and spleen 
T  cells but not in mature thymocytes, an intriguing  differ- 
ence between both compartments which was already observed 
in transgenic  mice (45).  Likewise, different anti-CD2  Abs 
lack as yet any demonstrable in vivo effect on intrathymic 
T  cell differentiation and selection (e.g.  deletion of V~6 + T 
cells in Mls~-positive  mouse strains [9, 53, 54]) which is in 
contrast to the marked effect on the immunocompetence of 
postthymic mature T  calls. 
The immunosuppressive effects of anti-CD2 Abs are poten- 
tially applicable for therapeutic intervention, e.g., prolonga- 
tion of allo-transplants or the treatment of autoimmune syn- 
dromes. 
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